RXi Pharmaceuticals Corporation (NASDAQ:RXII) shares were down 5.6% during mid-day trading on Tuesday . The stock traded as low as $0.63 and last traded at $0.67. Approximately 748,577 shares were traded during trading, an increase of 25% from the average daily volume of 600,605 shares. The stock had previously closed at $0.71.

RXi Pharmaceuticals (NASDAQ:RXII) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter last year, the business posted ($0.34) EPS. equities analysts expect that RXi Pharmaceuticals Corporation will post -0.74 earnings per share for the current fiscal year.

In related news, insider Alexey Eliseev sold 176,800 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the sale, the insider now owns 1,100,931 shares in the company, valued at $594,502.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.71% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “RXi Pharmaceuticals (RXII) Trading Down 5.6%” was first posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/11/30/rxi-pharmaceuticals-rxii-trading-down-5-6.html.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.